Aevi Genomic Medicine, Inc.
(NASDAQ : GNMX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.13%178.070.7%$1350.16m
MRKMerck & Co., Inc. -0.34%92.820.7%$1224.22m
PFEPfizer Inc. 0.69%53.120.9%$1139.60m
LLYEli Lilly & Co. -0.51%328.481.1%$1006.45m
BMYBristol-Myers Squibb Co. -0.88%75.551.0%$975.23m
ABBVAbbVie, Inc. -0.23%152.181.9%$958.35m
AZNAstraZeneca Plc 0.21%66.631.0%$468.29m
SGENSeagen Inc. 2.29%179.145.7%$331.29m
GSKGSK Plc 0.63%43.380.2%$274.56m
TPTXTurning Point Therapeutics, Inc. 0.11%75.260.0%$179.28m
NVSNovartis AG 0.79%84.390.2%$174.83m
HZNPHorizon Therapeutics Plc 1.69%83.865.4%$173.90m
ALNYAlnylam Pharmaceuticals, Inc. 1.59%152.398.1%$148.89m
NVONovo Nordisk A/S -0.36%110.090.1%$147.95m
MRTXMirati Therapeutics, Inc. -2.32%68.211.6%$135.68m

Company Profile

Aevi Genomic Medicine focuses on translating genetic discoveries into novel therapies. It is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the company's research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics at The Children's Hospital of Philadelphia.